Keywords: GlaxoSmithKline, Human Genome Sciences, Benlysta, Lupus erythematosus, SLE, USA, FDA advisory panel

GlaxoSmithKline and Human Genome see shares rise after getting US FDA advisory panel backing for lupus drug Benlysta

Article | 17 November 2010

Print This

The US Food and Drug Administration’s Arthritis Advisory Committee has voted 13 to two to recommend that the FDA ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in